FDA Signals Interest In Requiring Unique Biosimilar Names
This article was originally published in The Pink Sheet Daily
Executive Summary
OND Director Jenkins expresses concern at a public hearing that the agency could miss or confuse some spontaneous adverse events if biosimilars are not distinguished from their reference product.
You may also be interested in...
FDA's Biosimilar Strategy Will Rely On "Fingerprint" Technology To Limit Trials
European experiences with "totality of the evidence" method also seem to be shaping policy, according to FDA article in NEJM.
FDA's Biosimilar Strategy Will Rely On "Fingerprint" Technology To Limit Trials
European experiences with "totality of the evidence" method also seem to be shaping policy, according to FDA article in NEJM.